File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s13046-016-0295-1
- Scopus: eid_2-s2.0-84956945953
- WOS: WOS:000368477000003
Supplementary
- Citations:
- Appears in Collections:
Article: Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: Evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination
Title | Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: Evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination |
---|---|
Authors | |
Keywords | Antigen presentation Tumor immunity Tumor lysate Antigen loading Laryngeal cancer Dendritic cells |
Issue Date | 2016 |
Citation | Journal of Experimental and Clinical Cancer Research, 2016, v. 35, n. 1 How to Cite? |
Abstract | © 2016 Wei et al.Background: Dendritic cells (DCs) have been used successfully in clinical pilot studies. However, tumor-specific immunity and clinical responses were only induced in certain cancer patients. It has been well documented that immunotherapy efficacy can be optimized for responses using antigen pulsing. Methods: The human laryngeal squamous cell cancer (LSCC) cell line SNU899 was used to evaluate the in vitro anti-tumor efficacy of three different preparations of dendritic cell (DC) vaccines consisting of either whole tumor cells or their derivatives including: i) DCs pulsed with a tumor cell supernatant (DC-TCS), ii) DCs pulsed with whole-cell tumor stressed lysate (DC-TSL), and iii) DCs pulsed with irradiated tumor cells (DC-ITC). Results: Our results showed that DC-TSL is an effective source of tumor-associated antigens (TAAs) for pulsing DCs. DC-TSL induced the highest expansion of TAA-specific T cells, the strongest Th1 cytokine response, and the most potent cytotoxic T lymphocyte (CTL) activity. DC-TCS and DC-ITC inhibited T cell activation but induced a certain extent of CTL activity. Conclusions: These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal cancer than other antigen-loading strategies using whole tumor cell materials. This strategy provides an alternative approach for DC-based immunotherapy for laryngeal cancer. |
Persistent Identifier | http://hdl.handle.net/10722/235955 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wei, Fan Qin | - |
dc.contributor.author | Sun, Wei | - |
dc.contributor.author | Wong, Thian Sze | - |
dc.contributor.author | Gao, Wei | - |
dc.contributor.author | Wen, Yi Hui | - |
dc.contributor.author | Wei, Jia Wei | - |
dc.contributor.author | Wei, Yi | - |
dc.contributor.author | Wen, Wei Ping | - |
dc.date.accessioned | 2016-11-10T07:11:49Z | - |
dc.date.available | 2016-11-10T07:11:49Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Journal of Experimental and Clinical Cancer Research, 2016, v. 35, n. 1 | - |
dc.identifier.uri | http://hdl.handle.net/10722/235955 | - |
dc.description.abstract | © 2016 Wei et al.Background: Dendritic cells (DCs) have been used successfully in clinical pilot studies. However, tumor-specific immunity and clinical responses were only induced in certain cancer patients. It has been well documented that immunotherapy efficacy can be optimized for responses using antigen pulsing. Methods: The human laryngeal squamous cell cancer (LSCC) cell line SNU899 was used to evaluate the in vitro anti-tumor efficacy of three different preparations of dendritic cell (DC) vaccines consisting of either whole tumor cells or their derivatives including: i) DCs pulsed with a tumor cell supernatant (DC-TCS), ii) DCs pulsed with whole-cell tumor stressed lysate (DC-TSL), and iii) DCs pulsed with irradiated tumor cells (DC-ITC). Results: Our results showed that DC-TSL is an effective source of tumor-associated antigens (TAAs) for pulsing DCs. DC-TSL induced the highest expansion of TAA-specific T cells, the strongest Th1 cytokine response, and the most potent cytotoxic T lymphocyte (CTL) activity. DC-TCS and DC-ITC inhibited T cell activation but induced a certain extent of CTL activity. Conclusions: These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal cancer than other antigen-loading strategies using whole tumor cell materials. This strategy provides an alternative approach for DC-based immunotherapy for laryngeal cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Experimental and Clinical Cancer Research | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Antigen presentation | - |
dc.subject | Tumor immunity | - |
dc.subject | Tumor lysate | - |
dc.subject | Antigen loading | - |
dc.subject | Laryngeal cancer | - |
dc.subject | Dendritic cells | - |
dc.title | Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: Evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s13046-016-0295-1 | - |
dc.identifier.scopus | eid_2-s2.0-84956945953 | - |
dc.identifier.hkuros | 259256 | - |
dc.identifier.hkuros | 261415 | - |
dc.identifier.volume | 35 | - |
dc.identifier.issue | 1 | - |
dc.identifier.eissn | 1756-9966 | - |
dc.identifier.isi | WOS:000368477000003 | - |
dc.identifier.issnl | 1756-9966 | - |